Quest Diagnostics Incorporated (BMV:DGX)

Market Cap	365.60B +4.3%
Revenue (ttm)	199.01B +13.7%
Net Income	17.66B +15.2%
EPS	156.17 +14.5%
Shares Out	n/a
PE Ratio	20.70
Forward PE	18.24
Dividend	60.47 (1.82%)
Ex-Dividend Date	Jan 13, 2026

Volume	70
Average Volume	1,077
Open	3,330.00
Previous Close	3,200.00
Day's Range	3,330.00 - 3,330.00
52-Week Range	3,132.50 - 3,450.00
Beta	n/a
RSI	54.91
Earnings Date	Feb 10, 2026

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,...

• Industry: Medical Laboratories
• Founded: 1967
• Employees: 56,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: DGX

Financial Performance

In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.

Financial numbers in USD